OLMA
$14.08-0.88 (-5.88%)
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Recent News
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Weigh Tech Rally Against Geopolitical Risks
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.9% and the actively trad
A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback
Olema Pharmaceuticals (OLMA) is back in focus after Roche’s Phase 3 breast cancer trial for giredestrant missed its primary endpoint, a setback that coincided with a sharp 41% drop in Olema’s share price. See our latest analysis for Olema Pharmaceuticals. That reaction has not been limited to a single session either. The 7 day share price return is negative 33.91% and the 30 day share price return is negative 36.20% at a last close of US$14.91. At the same time, the 1 year total shareholder...
H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02
H.C. Wainwright notes that Roche’s (RHHBY) persevERA trial “disappointingly” failed, though the firm does not view the frontline opportunity as eliminated for palazestrant and does not believe the persevERA trial is “a complete readthrough” to Olema Oncology’s (OLMA) OPERA-02 trial, which is evaluating palazestrant plus ribociclib. Differences in combo agents could favor OPERA-02, argues the analyst, who keeps a Buy rating on Olema shares.Claim 70% Off TipRanks PremiumUnlock hedge fund-level dat